Tumor-specific, circulating cell-free DNA in liquid biopsies is a promising source of
biomarkers for minimally invasive serial monitoring of treatment responses in cancer …

An increasing number of studies demonstrate the potential use of cell-free DNA (cfDNA) as a
surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and …

Abstract “Liquid biopsy” focusing on the analysis of circulating tumor cells (CTC) and
circulating cell-free tumor DNA (ctDNA) in the blood of patients with cancer has received …

While various clinical applications especially in oncology are now in progress such as
diagnosis, prognosis, therapy monitoring, or patient follow-up, the determination of structural …

Breast cancer is the most common cancer among women worldwide. Due to its complexity in
nature, effective breast cancer treatment can encounter many challenges. Traditional …

Precision medicine in the clinical management of cancer may be achieved through the
diagnostic platform called “liquid biopsy”. This method utilizes the detection of biomarkers in …

The study of extracellular vesicles (EVs), especially in the liquid biopsy field, has rapidly
evolved in recent years. However, most EV studies have focused on RNA or protein content …

Cancer is associated with mutated genes, and analysis of tumour-linked genetic alterations
is increasingly used for diagnostic, prognostic and treatment purposes. The genetic profile of …

Cell-free DNA (cfDNA) is a widely used noninvasive biomarker for diagnosis and prognosis
of multiple disease states. Emerging evidence suggests that cfDNA might not just be passive …

Precision oncology is predicated upon the ability to detect specific actionable genomic
alterations and to monitor their adaptive evolution during treatment to counter resistance …